How Long Should You Take GLP-1 Medications? What the Research Shows

*Compounded semaglutide and compounded tirzepatide are not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Clinical data referenced here reflects studies of FDA-approved pharmaceutical compounds unless otherwise noted. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization.*

---

Most people start a GLP-1 program with a mental timeline in mind. Lose the weight. Stop the medication. Move on. It seems like a reasonable plan. But the clinical evidence tells a more complicated story, and understanding it before you start can save you from a frustrating experience later on.

The research is now consistent enough to offer real answers to a question that millions of people are asking: how long should you actually take semaglutide or tirzepatide?

---

Why the Question Matters More Than It Used to

For decades, weight loss medications were viewed as short-term interventions. You took them until you lost the weight, then you stopped. The medications available at the time were largely stimulants with significant side effect profiles and modest long-term data, which made that approach seem prudent.

GLP-1 receptor agonists are different. Not just in how they work, but in how the evidence has developed around them. We now have clinical trials running two to four years, real-world data from hundreds of thousands of patients, and a growing body of mechanistic research that illuminates why these medications behave the way they do.

That evidence has shifted how leading obesity specialists think about GLP-1 treatment. Not as a short course, but as a long-term management strategy for a chronic condition. Understanding why that shift happened starts with understanding what obesity actually is.

---

Obesity as a Chronic Condition

The clinical framing of obesity has changed significantly over the past decade. Medical organizations including the American Medical Association, the American Academy of Pediatrics, and the Obesity Medicine Association now classify obesity as a chronic, relapsing disease, not a lifestyle failure or a temporary state.

That reclassification matters for treatment decisions. Chronic conditions are managed, not cured. We don't tell someone with hypertension to stop their antihypertensive after their blood pressure normalizes. We don't expect someone with hypothyroidism to stop levothyroxine once their TSH is in range. The drug is managing a chronic biological process. If you remove the drug, the process resumes.

GLP-1 medications work, in part, by restoring a regulatory signal that obesity has disrupted. The brain's ability to register satiety, the gut's hormonal communication with appetite centers, the pancreas's insulin response - these are mechanisms that obesity impairs over time. GLP-1 receptor agonists support these systems. For most people, the biology that made weight management difficult does not disappear when they reach a lower weight.

---

What Happens When You Stop: The STEP 4 Trial

The clearest clinical evidence for understanding stopping versus continuing comes from the STEP 4 trial. Rubino and colleagues enrolled adults with overweight or obesity and placed all participants on semaglutide 2.4 mg for 20 weeks of run-in treatment. After 20 weeks, participants had achieved significant weight loss. Then the trial split them: one group continued on semaglutide for another 48 weeks, while the other switched to placebo.

The results were stark. The group that continued on semaglutide lost an additional 7.9 percent of body weight over the next 48 weeks. The group switched to placebo regained 6.9 percent. By the end of the trial, there was a nearly 14 percentage point difference in body weight between the two groups (PMID 33755728, Rubino D et al., JAMA 2021).

This was not a study of people who had maintained their weight for years. This was a study of people who had been on the medication for only 20 weeks and had already achieved meaningful weight loss. Even at that stage, stopping reversed most of those gains within about a year.

---

Weight Regain After Stopping: The STEP 1 Extension

The STEP 1 trial extension, published by Wilding and colleagues in 2022, traced what happened to participants after they completed the original STEP 1 trial and stopped semaglutide. The findings confirmed the pattern from STEP 4.

During the STEP 1 trial, participants lost an average of 14.9 percent of their body weight over 68 weeks. In the year after stopping, most of that weight returned. By one year post-treatment, participants had regained roughly two-thirds of what they had lost. The cardiometabolic improvements seen during treatment, including blood pressure, lipids, and blood sugar markers, similarly reverted (PMID 35441470, Wilding JPH et al., Diabetes Obes Metab 2022).

The mechanism here is not failure of willpower or poor habits. GLP-1 medications reduce appetite in part by acting on receptors in the hypothalamus and brainstem. When the medication is stopped, that signaling support is removed. The biological drive to eat resumes at the level it was before treatment.

For people whose obesity has a strong genetic or hormonal component, this is not a personal failure. It is the predictable pharmacological response.

---

What Two-Year Data Shows About Long-Term Use

The STEP 5 trial extended the evidence to two years, providing the longest-running major semaglutide efficacy and safety trial at the time of publication. Garvey and colleagues reported that participants who remained on semaglutide 2.4 mg for two full years maintained their weight loss and continued to achieve additional metabolic benefits. Average weight loss reached 15.2 percent from baseline at 104 weeks (PMID 36216945, Garvey WT et al., Nature Medicine 2022).

Importantly, the safety profile at two years was consistent with what had been seen in shorter trials. No new safety signals emerged. The pattern of gastrointestinal side effects was heavily front-loaded, concentrated in the first several weeks of treatment and during dose escalation, which is consistent with what most patients experience.

The two-year data changed the framing for many clinicians: if efficacy and safety hold at two years, the question is no longer "can someone take this long-term" but "what does long-term look like for different patients."

---

Four-Year Cardiovascular Safety: The SELECT Trial

For people managing obesity alongside cardiovascular disease risk, the SELECT trial provides the longest-running and most comprehensive safety dataset currently available for semaglutide. The trial enrolled over 17,000 adults with pre-existing cardiovascular disease who were overweight or obese but did not have diabetes. Participants were followed for up to five years.

The SELECT trial showed that semaglutide significantly reduced the risk of major adverse cardiovascular events, with a 20 percent relative risk reduction in the composite endpoint of cardiovascular death, non-fatal heart attack, and non-fatal stroke (PMID 37952131, Lincoff AM et al., N Engl J Med 2023). Critically, the study also provided safety data across a multi-year follow-up period at a population scale, with no new serious safety concerns emerging over time.

For patients who need long-term cardiovascular risk management alongside weight management, the SELECT data has become one of the most compelling arguments for sustained GLP-1 therapy.

---

Why Many People Stop Earlier Than Planned

While the clinical evidence supports long-term use for most people managing obesity, real-world data shows that a substantial portion of patients do not continue GLP-1 therapy for extended periods.

A 2026 study characterizing real-world discontinuation patterns found that a significant portion of patients who start a GLP-1 receptor agonist discontinue within six months (PMID 41713959, Van Laren J et al., Diabetes Obes Metab 2026). The reasons varied. Side effects, cost, difficulty accessing ongoing prescriptions, and the belief that they had completed the treatment were among the factors cited.

The gap between what the evidence supports and what happens in practice is partly a communication problem. Many people start these medications without understanding that reaching a goal weight is not the same as completing treatment for a chronic disease. The framework of obesity as a chronic condition is not yet widely shared in patient-facing communication.

---

Who Might Be Able to Stop

Not everyone who starts a GLP-1 program needs to stay on it indefinitely. There are clinical scenarios where tapering or stopping makes sense, and identifying them requires a conversation with a licensed healthcare provider, not a unilateral decision.

Patients who may be able to consider stopping include those who:

Have addressed primary drivers of obesity. For some people, weight gain was driven by a specific, correctable cause: a medication that caused weight gain (and has since been changed), untreated hypothyroidism (now managed), significant stress or a disruptive life period that has resolved. When the underlying driver has changed, the case for long-term GLP-1 therapy may be different.

Have maintained a stable weight for a meaningful period. While the STEP 1 extension shows that most people regain weight after stopping, the pattern is not universal. Some individuals, particularly those who have made substantial and durable changes to their eating patterns and activity levels, may have a different trajectory. This is best assessed with a provider who knows your history.

Have comorbidities that improve enough to change the risk-benefit calculation. If metabolic conditions that originally supported GLP-1 therapy have resolved, the calculus changes. A provider can evaluate whether the reasons for starting still apply.

Have reached the lower end of a healthy BMI range with stable habits. Continued weight loss below a clinical threshold may not be the goal, and the need for ongoing treatment should be reassessed.

In all of these scenarios, what matters is having an honest, structured conversation with a healthcare provider. Stopping abruptly based on feeling like you're done is different from making a deliberate, monitored decision.

---

The Role of Lifestyle Habits in Long-Term Success

A consistent finding across the GLP-1 clinical trials is that people who combine these medications with changes in eating patterns and physical activity tend to do better, both during treatment and, to a lesser degree, after stopping.

This is not a trivial point. GLP-1 medications create a window of opportunity. Reduced appetite makes it significantly easier to adopt lower-calorie eating patterns. The quieting of what many patients describe as constant food preoccupation makes space for developing new habits. If that window is used to build durable behavioral scaffolding, the medications may be more effective even after eventual tapering.

Exercise, particularly resistance training, plays a specific role in this context. GLP-1 medications reduce appetite in ways that can lead to reduced muscle mass if protein intake and strength training are not prioritized. People who focus on preserving lean muscle during treatment tend to emerge from a weight loss phase in a stronger metabolic position.

Lifestyle habits are not a replacement for pharmacological support when obesity is the underlying condition. But they are the part of the picture that patients have the most direct control over.

---

A Note on Compounded Semaglutide and Tirzepatide

The clinical data discussed throughout this article refers to studies conducted on FDA-approved semaglutide (Ozempic, Wegovy) and, where specified, FDA-approved tirzepatide (Mounjaro, Zepbound). Compounded versions of these medications are not FDA-approved. Their safety and efficacy have not been evaluated in the same controlled clinical trials.

Compounded semaglutide may be available through properly licensed 503A compounding pharmacies under specific patient circumstances. A provider in Prescriva's affiliated network can evaluate whether a compounded option is clinically appropriate for your situation and explain the regulatory context in full.

---

Having the Conversation With Your Provider

If you are currently on a GLP-1 program and wondering how long you will need to stay on it, the most important first step is raising that question directly with your prescribing provider. A productive conversation should cover your starting weight and current weight, your metabolic health markers before and after treatment, what specific conditions or risk factors motivated the prescription, and what your goals are for the next 12 to 24 months.

There is no universal answer to how long anyone should take a GLP-1 medication. The clinical evidence tells us that for most people managing obesity as a chronic condition, long-term use is associated with the best outcomes. But medicine is applied to individuals, and an individualized assessment matters.

---

The Bottom Line

The clinical picture is clearer than it was five years ago. For most people who use semaglutide or tirzepatide to manage obesity, stopping the medication results in meaningful weight regain. The STEP 4 and STEP 1 extension trials demonstrate this consistently. The STEP 5 and SELECT data show that long-term use is both safe and effective for appropriate candidates.

What this means practically is that starting a GLP-1 program with an accurate understanding of its nature as a chronic disease management tool, rather than a finite course of treatment, leads to better outcomes and more realistic expectations from the beginning.

The question is not whether you will eventually stop taking your medication. It may be that you will. The more useful question is: have you and your provider made that decision deliberately, based on your current health picture, rather than based on the assumption that reaching your goal weight means the work is done?

Ready to explore your options? Check your eligibility for a medically supervised GLP-1 program at Prescriva.

---

Sources

1. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. *JAMA.* 2021;325(14):1414-1425. PMID: 33755728
2. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. *Diabetes Obes Metab.* 2022;24(8):1553-1564. PMID: 35441470
3. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nat Med.* 2022;28(10):2083-2091. PMID: 36216945
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023;389(24):2221-2232. PMID: 37952131
5. Van Laren J, Patel S, Eriksson JW, et al. Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist. *Diabetes Obes Metab.* 2026. PMID: 41713959